Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

70.67
-0.2400-0.34%
Post-market: 70.670.00000.00%16:04 EDT
Volume:400.71K
Turnover:28.33M
Market Cap:3.93B
PE:6.36
High:71.61
Open:71.27
Low:70.14
Close:70.91
52wk High:74.59
52wk Low:59.47
Shares:55.60M
Float Shares:55.60M
Volume Ratio:0.77
T/O Rate:0.72%
Dividend:0.81
Dividend Rate:1.15%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.40
PE(LYR):23.10

Loading ...

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 24

Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 24

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

TIPRANKS
·
Sep 24

Medtronic PLC Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Exchange-Traded Funds, US Equities Decline After Midday

MT Newswires Live
·
Sep 24

Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy

MT Newswires Live
·
Sep 23

J&J Says New Model-Based Analysis Further Supports the Potential of Tecvayli Plus Darzalex Faspro

Reuters
·
Sep 23

Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control

TIPRANKS
·
Sep 23

J&J Says MajesTEC-3 Analysis Projects Near-General-Population Mortality Risk for Tecvayli-Darzalex Combo in Early Relapsed Myeloma

Reuters
·
Sep 23

J&J - Tecvayli Plus Darzalex Faspro Reduces Multiple Myeloma Progression Risk by 90% Versus Standard of Care

THOMSON REUTERS
·
Sep 23

New Model-Based Analysis Further Supports the Potential of Tecvayli® (Teclistamab-Cqyv) Plus Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj) to Redefine Long-Term Survival Expectations in Early Line Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 23

J&J - Analysis Estimates 87% of Tecvayli Plus Darzalex Faspro Patients Have Comparable Mortality Risk to General Population

THOMSON REUTERS
·
Sep 23

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday as Traders Await Developments in US-Iran Talks

MT Newswires Live
·
Sep 23

Oruka Falls After Reporting Mid-Stage Data for Psoriasis Drug

Reuters
·
Sep 23